{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.1"},{"groupId":"OG001","value":"25.6"}]}],"title":"V1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1"},{"groupId":"OG001","value":"7.7"}]}],"title":"V2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4"},{"groupId":"OG001","value":"1.3"}]}],"title":"V3a"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3"},{"groupId":"OG001","value":"6.4"}]}],"title":"V3a/b"},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.0"},{"groupId":"OG001","value":"59.0"}]}],"title":"No rearrangement"}],"denoms":[{"counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"78"}],"units":"Participants"}],"description":"The Response Genetics, Inc. Echinoderm Microtubule Associated Protein Like 4 (EML4) ALK reverse transcriptase polymerase chain reaction (RT PCR) gene fusion test was used for the analysis of tissue samples for the ALK gene fusion variants (either no rearrangement, or 1 of 9 results reflecting 8 specific rearrangements \\[V1, V2, V3a, V3b,V3a/b, V4, V5a, V6, V7\\]). Percentage of participants who tested positive for ALK gene fusion variants were reported in this outcome measure.","groups":[{"description":"Crizotinib 250 mg capsule, orally twice daily was administered in treatment cycle of 21 days. Participants could continue crizotinib treatment beyond the time of RECIST v1.1 defined PD, as determined by IRR, at the discretion of the investigator if the participant was perceived to be experiencing clinical benefit.","id":"OG000","title":"Crizotinib"},{"description":"Standard doses of chemotherapy (pemetrexed/cisplatin or pemetrexed/carboplatin) were administered intravenously on Day 1 of each cycle for a maximum of 6 cycles. Pemetrexed 500 mg per meter square (m)\\^2 IV infusion according to standard of care was administered over 10 min; either cisplatin 75 mg/m\\^2 IV infusion was administered approximately 30 min after the end of the pemetrexed infusion or carboplatin was administered at a dose calculated to produce an AUC of 5 or 6 mg\\*min/mL, approximately 30 min after end of pemetrexed infusion.","id":"OG001","title":"Chemotherapy"}],"paramType":"NUMBER","populationDescription":"The ALK variant evaluable population included participants from the FA population who had a result from ALK gene fusion variant testing of either no rearrangement, or 1 of 9 results reflecting 8 specific rearrangements (V1, V2, V3a, V3b, V3a/b, V4, V5a, V6, and V7).","reportingStatus":"POSTED","timeFrame":"28 days prior to day 1 of study treatment","title":"Percentage of Participants For Each Anaplastic Lymphoma Kinase (ALK) Gene Fusion Variants","type":"SECONDARY","unitOfMeasure":"percentage of participants"}